Overview

12-Month, Open-Label, Extension Study of LCP-AtorFen in Dyslipidemia

Status:
Completed
Trial end date:
2009-02-01
Target enrollment:
Participant gender:
Summary
The current study is designed to test the long-term (12-month) safety and efficacy of LCP-AtorFen, a combination of atorvastatin and fenofibrate, in patients with dyslipidemia
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Veloxis Pharmaceuticals
Treatments:
Atorvastatin
Atorvastatin Calcium
Fenofibrate